Asia-pacific Skin Cancer Diagnostics Market Forecast 2023-2032

Asia-pacific Skin Cancer Diagnostics Market Forecast 2023-2032


KEY FINDINGS

The Asia-Pacific skin cancer diagnostics market is set to project a 7.76% CAGR during 2023-2032. The increasing awareness regarding the importance of early detection and regular screening is contributing to increased demands for diagnostic tests in the region.

MARKET INSIGHTS

China, Indonesia, South Korea, Japan, Australia & New Zealand, Vietnam, Thailand, India, and Rest of Asia-Pacific are evaluated for the growth assessment of the Asia-Pacific skin cancer diagnostics market. In Japan, the market growth is driven by the increasing prevalence of skin cancer and government initiatives. For instance, the government accords the largest share of expenses, more than 38%, through the national treasury and municipality funds. Besides, new medical tools are being launched by market players. For instance, PHC Corporation and US-based NovaScan announced a collaboration in April 2023. They aim to explore the feasibility of MarginScan, an investigational ‘ex vivo’ medical device to support the detection of non-melanoma skin cancers (NMSC).

Further, in South Korea, the market growth is attributed to considerable advancements in dermatology-related technologies and growing skin cancer awareness among the population. Also, as per the 2020 World Health Organization (WHO) 2020 data, skin cancer deaths in the country constituted 0.23% of total deaths. Additionally, the skin cancer melanoma treatment costs between $3150 to $3850. Similarly, the per capita spending has been on a steady rise in the country. Such factors boost the market growth in these countries.

COMPETITIVE INSIGHTS

Some of the eminent companies operating in the market include F Hoffmann-La Roche Ltd, Michelson Diagnostics Ltd, AMLo Biosciences Limited, etc.

Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation caters to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• The competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments


1. Research Scope & Methodology
1.1. Study Objectives
1.2. Methodology
1.3. Assumptions & Limitations
2. Executive Summary
2.1. Market Size & Estimates
2.2. Market Overview
2.3. Scope Of Study
2.4. Crisis Scenario Analysis
2.5. Major Market Findings
2.5.1. Increasing Application Of Ai And Machine Learning In Skin Cancer Diagnosis Tools
2.5.2. Expanding Market Demand For Skin Cancer Diagnostics In Australia
3. Market Dynamics
3.1. Key Drivers
3.1.1. Increasing Prevalence Of Skin Cancer
3.1.2. Growing Awareness About Skin Cancer Diagnosis & Treatment
3.1.3. Technological Advancements In Skin Cancer Diagnostic Products
3.2. Key Restraints
3.2.1. High Costs Associated With Skin Cancer Treatments
3.2.2. Stringent Regulatory Framework
3.2.3. Lack Of Skilled Medical Professionals
4. Key Analytics
4.1. Parent Market Analysis
4.2. Key Market Trends
4.3. Porter’s Five Forces Analysis
4.3.1. Buyers Power
4.3.2. Suppliers Power
4.3.3. Substitution
4.3.4. New Entrants
4.3.5. Industry Rivalry
4.4. Growth Prospect Mapping
4.5. Market Concentration Analysis
4.6. Value Chain Analysis
4.6.1. Research And Development
4.6.2. Manufacturing
4.6.3. Marketing And Sales
4.6.4. Distribution And Logistics
4.6.5. Training And Support
5. Market By Type
5.1. Melanoma
5.2. Non-melanoma
6. Market By Gender
6.1. Male
6.2. Female
7. Market By Screening Type
7.1. Skin Biopsy
7.2. Dermatoscopy
7.3. Lymph Node
7.4. Biopsy Imaging Tests
7.5. Blood Tests
8. Geographical Analysis
8.1. Asia-pacific
8.1.1. Market Size & Estimates
8.1.2. Asia-pacific Skin Cancer Diagnostics Market Drivers
8.1.3. Asia-pacific Skin Cancer Diagnostics Market Challenges
8.1.4. Key Players In Asia-pacific Skin Cancer Diagnostics Market
8.1.5. Country Analysis
8.1.5.1. China
8.1.5.1.1. China Skin Cancer Diagnostics Market Size & Opportunities
8.1.5.2. Japan
8.1.5.2.1. Japan Skin Cancer Diagnostics Market Size & Opportunities
8.1.5.3. India
8.1.5.3.1. India Skin Cancer Diagnostics Market Size & Opportunities
8.1.5.4. South Korea
8.1.5.4.1. South Korea Skin Cancer Diagnostics Market Size & Opportunities
8.1.5.5. Indonesia
8.1.5.5.1. Indonesia Skin Cancer Diagnostics Market Size & Opportunities
8.1.5.6. Thailand
8.1.5.6.1. Thailand Skin Cancer Diagnostics Market Size & Opportunities
8.1.5.7. Vietnam
8.1.5.7.1. Vietnam Skin Cancer Diagnostics Market Size & Opportunities
8.1.5.8. Australia & New Zealand
8.1.5.8.1. Australia & New Zealand Skin Cancer Diagnostics Market Size & Opportunities
8.1.5.9. Rest Of Asia-pacific
8.1.5.9.1. Rest Of Asia-pacific Skin Cancer Diagnostics Market Size & Opportunities
9. Competitive Landscape
9.1. Key Strategic Developments
9.1.1. Product Launches & Developments
9.1.2. Partnerships & Agreements
9.2. Company Profiles
9.2.1. Amlo Biosciences Limited
9.2.2. Biomerieux Sa
9.2.3. Castle Biosciences Inc
9.2.4. Dermlite Llc
9.2.5. Dermtech Inc.
9.2.6. F Hoffmann-la Roche Ltd
9.2.7. Michelson Diagnostics Ltd
9.2.8. Neracare Gmbh
9.2.9. Skylinedx Bv
9.2.10. Veriskin Inc

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings